Header Logo

Nancy Reau

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentHepatology
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 15756529900.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Strzepka J, Schwartz BA, Ritz EM, Aloman C, Reau N. Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and Outcomes. J Clin Gastroenterol. 2024 Jan 01; 58(1):91-97. PMID: 36729430.
      Citations:    
    2. Malhi H, Brown RS, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Clin Liver Dis (Hoboken). 2023 Dec; 22(6):193-194. PMID: 38143807.
      Citations:    
    3. Malhi H, Brown RS, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology. 2023 Dec 01; 78(6):1680-1681. PMID: 37941421.
      Citations:    
    4. Malhi H, Brown RS, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Liver Transpl. 2023 12 01; 29(12):1262-1263. PMID: 37941408.
      Citations:    
    5. Malhi H, Brown RS, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatol Commun. 2023 Nov 01; 7(11). PMID: 37941420.
      Citations:    
    6. Loftus M, Brown RS, El-Farra NS, Owen EJ, Reau N, Wadei HM, Bernstein D. Improving the Management of Hepatorenal Syndrome-Acute Kidney Injury Using an Updated Guidance and a New Treatment Paradigm. Gastroenterol Hepatol (N Y). 2023 Sep; 19(9):527-536. PMID: 37771795.
      Citations:    
    7. Post Z, Reau N. What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages? Clin Liver Dis. 2023 11; 27(4):973-984. PMID: 37778780.
      Citations:    
    8. Ratziu V, Reau N. Reply: More questions than answers-Response to the POP-NEXT project. Hepatology. 2023 Aug 01; 78(2):E38. PMID: 37329168.
      Citations:    
    9. Reau N, Cheng WH, Shao Q, Marx SE, Brooks H, Martinez A. Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Na?ve, Compensated Cirrhotic HCV Patients. Infect Dis Ther. 2023 Jul; 12(7):1849-1860. PMID: 37329414.
      Citations:    
    10. Jung JH, Bhaimia E, Reau N. Use of tecovirimat for mpox infection followed by JYNNEOS vaccination postinfection in a liver transplant recipient. Transpl Infect Dis. 2023 Jun; 25(3):e14030. PMID: 36864644.
      Citations:    
    11. Reau NS. Hepatocellular Carcinoma and Hepatitis Delta Virus. Gastroenterol Hepatol (N Y). 2023 Mar; 19(3):155-157. PMID: 37706110.
      Citations:    
    12. Cavazos K, Eswaran S, Maidlow C, Keklik Karadag F, Idilman R, Idilman I, Miller I, Shammo J, Reau N, Ustun C. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis. Blood Adv. 2022 10 25; 6(20):5630-5633. PMID: 35839085.
      Citations:    
    13. Karim G, Giri D, Kushner T, Reau N. Evaluation of Liver Disease in Pregnancy. Clin Liver Dis. 2023 02; 27(1):133-155. PMID: 36400462.
      Citations:    
    14. Matos LR, Reau NS. The Spectrum of Hepatic Critical Care During Pregnancy: A Clinical Review. Clin Obstet Gynecol. 2023 03 01; 66(1):176-185. PMID: 36657053.
      Citations:    
    15. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. Am J Gastroenterol. 2022 10 01; 117(10S):44-52. PMID: 36194033.
      Citations:    
    16. Kim M, Hui KM, Shi M, Reau N, Aloman C. Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma. Hepatol Commun. 2022 11; 6(11):3247-3259. PMID: 36097402.
      Citations:    
    17. Schwartz B, Al-Sabti R, Reau N. Late-Onset Acute Liver Injury From Azathioprine. ACG Case Rep J. 2022 Sep; 9(9):e00847. PMID: 36134121.
      Citations:    
    18. Hoenigl M, Abramovitz D, Flores Ortega RE, Martin NK, Reau N. Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clin Infect Dis. 2022 Aug 24; 75(1):e955-e961. PMID: 35234860.
      Citations:    
    19. Jensen DM, Rzepczynski A, Jensen EE, Reau N. The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents. Hepatology. 2022 09; 76(3):854-859. PMID: 35416324.
      Citations:    
    20. Ratziu V, Anstee QM, Wong VW, Schattenberg JM, Bugianesi E, Augustin S, Gheorghe L, Zambon V, Reau N. An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project. Hepatology. 2022 12; 76(6):1766-1777. PMID: 35363906.
      Citations:    
    21. Chaillon A, Wynn A, Kushner T, Reau N, Martin NK. Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357. PMID: 32282879.
      Citations:    
    22. Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, Marx SE, Hayes OA, Manthena SR, Chirikov V, Dylla DE, Brooks H, Carabino JM, Saab S. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790. PMID: 34704194.
      Citations:    
    23. Van J, Reau N. Disseminated AIDS-Related Kaposi Sarcoma Immune Reconstitution Inflammatory Syndrome With Infiltrative Liver Disease. ACG Case Rep J. 2021 Sep; 8(9):e00660. PMID: 34646902.
      Citations:    
    24. Van J, Aloman C, Reau N. Potential Bias and Misconceptions in Liver Transplantation for Alcohol- and Obesity-Related Liver Disease. Am J Gastroenterol. 2021 10 01; 116(10):2089-2097. PMID: 34193797.
      Citations:    
    25. Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology. 2021 08; 74(2):1049-1064. PMID: 33577086.
      Citations:    
    26. Kushner T, Reau N. Had Anyone Considered the Donors? Fertility and Pregnancy Outcomes Among Female Living Donors. Liver Transpl. 2021 09; 27(9):1235-1236. PMID: 34118122.
      Citations:    
    27. McGuire FH, Andr? K, Bradsher ML, Harrison D, Sterling RK, Reddy KR, Serper M, Golin CE, Reau N, Lim JK, Nelson DR, Sarkar S, Evon DM. Willingness to participate in research among black patients with liver disease: A national cross-sectional study. J Viral Hepat. 2021 07; 28(7):982-993. PMID: 33665897.
      Citations:    
    28. L Volk M, Reau N. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient-Friendly Summary of the 2019 AASLD Guidelines. Clin Liver Dis (Hoboken). 2021 Feb; 17(2):85-89. PMID: 33680442.
      Citations:    
    29. Serper M, Evon DM, Amador J, Stewart PW, Sarkar S, Lok AS, Sterling RK, Reeve BB, Golin CE, Rajender Reddy K, Lim JK, Reau N, Nelson DR, Di Bisceglie AM, Fried MW. Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704. PMID: 33387381.
      Citations:    
    30. Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, Gaspar R, LaBrecque D, Lee A, Macedo G, McMahon B, Ning Q, Reau N, Sonderup M, van Leeuwen DJ, Armstrong D, Yurdaydin C. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021 01; 55(1):1-11. PMID: 33230011.
      Citations:    
    31. Kushner T, Reau N. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741. PMID: 33248169.
      Citations:    
    32. Sulkowski M, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C. Adv Ther. 2021 01; 38(1):423-440. PMID: 33145648.
      Citations:    
    33. Dieterich DT, Bernstein D, Flamm S, Pockros PJ, Reau N. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther. 2020 10; 52(8):1311-1322. PMID: 32813292.
      Citations:    
    34. Asselah T, Zeuzem S, Reau N, Hwang P, Long J, Talwani R, Robertson MN, Haber BA. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332. PMID: 32459122.
      Citations:    
    35. Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun. 2020 Mar; 4(3):329-341. PMID: 32140652.
      Citations:    
    36. Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Reddy KR, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS?CO13 HEPAVIH)". J Hepatol. 2020 03; 72(3):592-593. PMID: 31889556.
      Citations:    
    37. Chaillon A, Rand EB, Reau N, Martin NK. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895. PMID: 30689769.
      Citations:    
    38. Orekondy N, Cafardi J, Kushner T, Reau N. HCV in Women and Pregnancy. Hepatology. 2019 11; 70(5):1836-1840. PMID: 31135999.
      Citations:    
    39. Serper M, Evon DM, Stewart PW, Lok AS, Amador J, Reeve BB, Golin CE, Fried MW, Reddy KR, Sterling RK, Sarkar S, Di Bisceglie AM, Lim JK, Nelson DR, Reau N. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020. PMID: 31659661.
      Citations:    
    40. Singal AK, Satapathy SK, Reau N, Wong R, Kuo YF. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101. PMID: 31582326.
      Citations:    
    41. Schwartz M, O'Brien C, Raya N, Reau N. Acquired Hemophagocytic Lymphohistiocytosis Associated With Disseminated Herpes Simplex Virus in Immunocompetent Host. ACG Case Rep J. 2019 Aug; 6(8):e00164. PMID: 31737703.
      Citations:    
    42. Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497. PMID: 31096006.
      Citations:    
    43. Kushner T, Cafardi J, Reau N. Considering direct-acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier? Ther Adv Infect Dis. 2019 Jan-Dec; 6:2049936119838229. PMID: 30984395.
      Citations:    
    44. Ma K, Berger D, Reau N. Liver Diseases During Pregnancy. Clin Liver Dis. 2019 05; 23(2):345-361. PMID: 30947881.
      Citations:    
    45. Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908. PMID: 30067745.
      Citations:    
    46. Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307. PMID: 29672891.
      Citations:    
    47. Reau N. Pregnancy after liver transplantation: Can renal function quell the fear? Liver Transpl. 2018 05; 24(5):583-584. PMID: 29626391.
      Citations:    
    48. VanWagner LB, Reau N. Clinical Liver Disease: Introducing hot topics in hepatology. Clin Liver Dis (Hoboken). 2018 Feb; 11(2):33-34. PMID: 30147866.
      Citations:    
    49. Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011. PMID: 29377191.
      Citations:    
    50. Soriano V, Young B, Reau N. Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70. PMID: 29369303.
      Citations:    
    51. Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903. PMID: 29221887.
      Citations:    
    52. Reau N, Robertson MN, Feng HP, Caro L, Yeh WW, Nguyen BT, Wahl J, Barr E, Hwang P, Klopfer SO. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. Hepatol Commun. 2017 10; 1(8):757-764. PMID: 29404492.
      Citations:    
    53. Reau N, Nelson DR. HBV reactivation after HCV eradication: Deja Vu. Liver Int. 2017 07; 37(7):1088. PMID: 28635166.
      Citations:    
    54. Reau NS. Pangenotypic regimens and the next generation hepatitis C virus therapy. Clin Liver Dis (Hoboken). 2017 Jun; 9(6):131-133. PMID: 30992976.
      Citations:    
    55. Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017 07; 1(5):439-452. PMID: 29404471.
      Citations:    
    56. Kanwal F, Bacon BR, Beste LA, Brill JV, Gifford AL, Gordon SC, Horberg MA, Manthey JG, Reau N, Rustgi VK, Younossi ZM. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598. PMID: 28442121.
      Citations:    
    57. Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119. PMID: 28350558.
      Citations:    
    58. Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, Reau N, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68. PMID: 28342989.
      Citations:    
    59. Tran TT, Ahn J, Reau NS. Corrigendum: ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 11; 111(11):1668. PMID: 27808138.
      Citations:    
    60. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218. PMID: 27506929.
      Citations:    
    61. Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1. PMID: 27486034.
      Citations:    
    62. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Br?u N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048. PMID: 27444413.
      Citations:    
    63. Jensen DM, Sebhatu P, Reau NS. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8. PMID: 27306302.
      Citations:    
    64. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Vila RP, Liu L, Pedrosa M, Moller J, Reau N. Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 07; 111(7):1077. PMID: 27356843.
      Citations:    
    65. Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30. PMID: 26642977.
      Citations:    
    66. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L, Pedrosa M, Moller J, Reau N. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51. PMID: 27045929.
      Citations:    
    67. Desai AP, Reau N. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9. PMID: 26782133.
      Citations:    
    68. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196. PMID: 26832651.
      Citations:    
    69. Reau N, Fried MW, Nelson DR, Brown RS, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502. PMID: 26509462.
      Citations:    
    70. Foster GR, Afdhal N, Roberts SK, Br?u N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourli?re M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17. PMID: 26575258.
      Citations:    
    71. Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v. PMID: 26466649.
      Citations:    
    72. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, H?zode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44. PMID: 25942724.
      Citations:    
    73. Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med. 2015; 7:11-20. PMID: 25926761.
      Citations:    
    74. Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5. PMID: 25742912.
      Citations:    
    75. Reau N. HCV testing and linkage to care: Expanding access. Clin Liver Dis (Hoboken). 2014 Aug; 4(2):31-34. PMID: 30992916.
      Citations:    
    76. Desai AP, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau N, Meltzer DO, Jensen D. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6. PMID: 24100752.
      Citations:    
    77. Aronsohn A, Reau N, Jensen D. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91. PMID: 24806752.
      Citations:    
    78. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9. PMID: 24493069.
      Citations:    
    79. Reau N. Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):114-6. PMID: 23962550.
      Citations:    
    80. Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology. 2013 Jul; 58(1):422-7. PMID: 23460345.
      Citations:    
    81. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305. PMID: 23269576.
      Citations:    
    82. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat. 2012; 2012:138302. PMID: 23094146.
      Citations:    
    83. Desai AP, Reau N, Reddy KG, Te HS, Mohanty S, Satoskar R, Devoss A, Jensen D. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. Therap Adv Gastroenterol. 2012 Sep; 5(5):275-83. PMID: 22973414.
      Citations:    
    84. Mufti AR, Reau N. A pregnant patient with a positive hepatitis B surface antigen. Frontline Gastroenterol. 2013 Jan; 4(1):12-19. PMID: 28839696.
      Citations:    
    85. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32. PMID: 22554357.
      Citations:    
    86. Mufti AR, Reau N. Liver disease in pregnancy. Clin Liver Dis. 2012 May; 16(2):247-69. PMID: 22541697.
      Citations:    
    87. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82. PMID: 22314423.
      Citations:    
    88. Desai AP, Reau N. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95. PMID: 21867932.
      Citations:    
    89. Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102. PMID: 22239499.
      Citations:    
    90. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8. PMID: 21063395.
      Citations:    
    91. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71. PMID: 19448563.
      Citations:    
    92. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8. PMID: 18796095.
      Citations:    
    93. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother. 2008 Aug; 62(2):224-8. PMID: 18480168.
      Citations:    
    94. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x. PMID: 18242505.
      Citations:    
    95. Reau N. Best of AASLD 2006. Gastroenterol Hepatol (N Y). 2007 Jan; 3(1):51-4. PMID: 21960777.
      Citations:    
    96. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. Gastroenterol Hepatol (N Y). 2006 Jul; 2(7):504-508. PMID: 28289353.
      Citations:    
    Reau's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (260)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _